A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
RemeGen Co., Ltd.
RemeGen Co., Ltd.
Sun Yat-sen University
Fudan University
Beijing Biostar Pharmaceuticals Co., Ltd.
Beijing Biostar Pharmaceuticals Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
National Cancer Institute, Naples
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Jiangsu HengRui Medicine Co., Ltd.
NSABP Foundation Inc
Sun Yat-sen University
Göteborg University
Sixth Affiliated Hospital, Sun Yat-sen University
Scandinavian Prostate Cancer Group
Assiut University
BeyondSpring Pharmaceuticals Inc.
Zhejiang Cancer Hospital
University of Turin, Italy
Sun Yat-sen University
ChineseAMS
Henan Cancer Hospital
West China Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Sichuan Cancer Hospital and Research Institute
Tianjin Medical University Cancer Institute and Hospital
Fudan University
Institute of Cancer Research, United Kingdom
Guilin Medical University, China
Zhejiang Cancer Hospital
Tianjin Medical University Cancer Institute and Hospital
NSABP Foundation Inc
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Shanghai University of Traditional Chinese Medicine
Martin-Luther-Universität Halle-Wittenberg
China Breast Cancer Clinical Study Group
Sun Yat-sen University
Zhejiang Cancer Hospital
Sun Yat-sen University
Sun Yat-sen University
Air Force Military Medical University, China
Guangdong Association of Clinical Trials
Sun Yat-sen University
Sun Yat-sen University
Sun Yat-sen University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Xinjiang Medical University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)